MarketPulse

Phase 3b trial

3 articles
BenzingaBenzinga··Prnewswire

Brainstorm Cell Therapeutics Completes $2M February Fundraising Round

Brainstorm Cell Therapeutics raised $2M in February through private placement at $0.60/share. Funds support general operations, regulatory work, and Phase 3b trial preparations for ALS therapy NurOwn.
BCLIprivate placementcapital raise
BenzingaBenzinga··Prnewswire

Brainstorm Cell Raises $1M Through Private Placement Above Current Valuation

Brainstorm Cell raised $1M via private placement at $0.60/share, above market price. Funds support Phase 3b ALS therapy trials and regulatory efforts.
BCLIprivate placementstem cell therapy
BenzingaBenzinga··Vandana Singh

Eli Lilly's Dual-Therapy Approach Demonstrates Enhanced Efficacy in Psoriasis-Obesity Treatment

Eli Lilly's combo therapy of Taltz and Zepbound showed superior results for psoriasis-obesity patients, achieving 27.1% complete skin clearance versus 5.8% for monotherapy.
LLYCSLLYPhase 3b trialZepbound